Skip to content

Treatment With Benzodiazepine After Cardiac Surgery

The Influence of Short Term Treatment With Benzodiazepine After Cardiac Surgery

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02776228
Enrollment
200
Registered
2016-05-18
Start date
2016-12-31
Completion date
2018-04-30
Last updated
2016-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Brief summary

The study deals with the prevalence of insomnia after heart surgery and the outcome of treatment with Benzodiazepine for this phenomena.

Detailed description

Patients after heart surgery develop sleep disorder in the form of Insomnia. This finding is known and described in the literature with respect to a large number of major operations such as the pneumonectomy, esophageal resection, pancreatic surgery, liver surgery and so on. In the general population, Insomnia is a common disorder and describe in more than 50% in adults over the age of 50. In patients with comorbidity among other things, heart disease indicates a rate of up to 85% of chronic insomnia. The reasons for insomnia after multiple heart surgery, including emotional stress that accompanies the patient after surgery, pain and prolonged hospitalization in the hospital. In this study, aim to compare the results of short-term treatment with sleep medication after heart surgery on morbidity and immediate recovery. This study will allow us to examine the effect of sleep medication therapy in patients receiving treatment compared to patients who did not receive treatment.

Interventions

Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.

DRUGplacebo

Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 18 and older. 2. Applicants hospital for open heart surgery

Exclusion criteria

1. patients who came to emergency heart surgery. 2. patients who are not hemodynamically or respiratory stable 3. Patients who were taking hypnotic drugs on a daily basis before surgery. 4. Patients with low compliance that will not be able to fill out a sleep diary 5. lactose intolerance (due to components placebo) 6. Patients who can not take medication by one or more of the following: * pregnant. * nursing. * Patients with severe respiratory insufficiency * Patients with liver failure. * Patients who are addicted to alcohol * Patients without psychiatric background.

Design outcomes

Primary

MeasureTime frameDescription
Assessing chronic insomnia1 yearThe following outcome will be evaluated by Pittsburgh sleep quality index questionnaire before heart surgery.

Secondary

MeasureTime frameDescription
Reducing insomnia in post cardiac surgery1 yearThe following outcome will be evaluated by Pittsburgh sleep quality index questionnaire after heart surgery.

Contacts

Primary Contacttom mr fridman, MD
tomalach@gmail.com0542220892
Backup Contactdaniel ms haber, MA
d_haber@rambam.health.gov.il0526138901

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026